Salute e Benessere

Global Gastroparesis Treatment Market is Expected to Grow Revenue up to USD…

Gastroparesis, a debilitating condition characterized by delayed stomach emptying, is most commonly associated with diabetes. High blood glucose levels can lead to nerve chemical alterations and harm to blood vessels supplying nerves with oxygen and nutrients. Additionally, Idiopathic Gastroparesis (IG), a condition with various potential causes, further emphasizes the need for effective treatments. Patients with IG may experience nerve damage, muscle problems, or other medical conditions, such…

Reminder: Invitation: Sobi's Q3 2023 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards onsobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031 United Kingdom : +44 207 107 06 13 United States : +1 631 570 56 13 For other...

Global Allergen Blocker Market is Projected to Reach Around USD 214.5 Million By…

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/501 To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/501 The report highlights that allergen blockers are products designed to mitigate or prevent allergy symptoms by blocking or neutralizing environmental allergens such as mold spores, dust mites, pet dander, and pollen. These devices employ various...

New Drug Application Approval by the Pharmaceutical Administration Bureau of…

CONTACT: CONTACT: For further information, please contact : Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact persons set out above, onOctober 27, 2023at09:15 a.m. CET. The following files are available for download: View original content:...

CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)

A shareholder who wishes to participate in the extraordinary general meeting must (i) be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on the 13thNovember 2023, and (ii) notify its intention to participate in the extraordinary general meeting no later than the 15thNovember 2023, either by post to "Bolagsstämma", Immunovia AB, Scheelevägen 2, 223 63 Lund, Sweden or via email to bolagsstamma@immunovia.com. A participation notice shall…

World Stroke Day: World Stroke Organization calls for Action on Prevention as…

'The devastation caused by stroke deaths and disabilities is not inevitable', said WSO President Prof Sheila Martins 'Stroke is highly preventable, with easily identifiable risk factors such as high blood pressure, atrial fibrillation, smoking, physical inactivity, diabetes, high cholesterol, tobacco and alcohol use. These manageable risks account for around 90% of all strokes. There are clear and cost-effective recommendations and interventions that can be easily implemented, and that we know…

Orexo announces changes in the company´s Board of Directors

Robin Evers has more than 25 years of experience in the pharmaceutical industry, with expertise in the development of biologics, vaccines, and small molecule drugs from leading positions at Wyeth, Pfizer and since 2013 at Novo Nordisk A/S in Denmark. At Novo Nordisk A/S, Robin Evers is a member of the global R&D management team and has been instrumental in curating international strategies to support the development and registration of innovative and well-differentiated products, such as the…

Electrolux Group Q3 2023 Interim report

President and CEO Jonas Samuelson's comment President and CEOJonas Samuelson'scomment Organic sales declined by 7.9% in the third quarter. Like in the previous quarter, volumes declined significantly and as expected, net price was negative. We continued to execute well on the Group-wide cost reduction andNorth Americaturnaround program. However, the challenging market environment with demand mainly driven by forced replacements, consumers shifting to lower price points and high...

Banish the 'Crumbarrassment' with Bosch: Parents search for snack time savior

The research, commissioned by Bosch, also highlighted the snacks that are the biggest crumb culprits are sausage rolls, crusty bread and Cadbury's flakes. Weetabix, grated cheese and shortbread biscuits were among the other top contenders. The research, commissioned by Bosch, also highlighted the snacks that are the biggest crumb culprits are sausage rolls, crusty bread and Cadbury's flakes. Weetabix, grated cheese and shortbread biscuits were among the other top contenders. A particular...

Nexstim Plc Business Update Q3 2023

Press release, Helsinki, 27 October 2023 at 9 AM (EEST)Nexstim Plc Business Update Q3 2023 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company's business operations during Q3 2023. CEO Mikko Karvinen's Business Update During the third quarter of 2023, we have continued our focus on projects that are crucial for the company's strategic competitive advantage, such as improving the company's cost efficiency through our new global team structures...

Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and…

Specialty Care growth, strong launch uptake of Beyfortus ®and ALTUVIIIO ®drive solid Q3 results Paris, October 27, 2023Q3 2023 sales growth of 3.2% at CER and business EPS (1)decrease of 2.1% at CERSpecialty Care grew 13.5% driven by Dupixent ®(€2,847 million, +32.8%) and ALTUVIIIO ®more than offsetting the impact of Aubagio ®generic competition in the U.S.Stable Vaccines sales (-0.6%) benefited from strong Beyfortus ®launch offsetting lower...

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Sanofi Enters Next Chapter of Play to Win Strategy Increases investments in its pipeline to fully realize long-term growth potential, bolstered by successful launches and R&D progress.Launches strategic cost initiatives, with most of the savings to be reallocated to fund innovation and growth drivers.Announces intention to separate the Consumer Healthcare Business at the earliest in Q4 2024 via the creation of a publicly listed entity headquartered in France.Reiterates...

[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche's Vabysmo for…

RVO is the third indication for Vabysmo, in addition to neovascular or 'wet' age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept Vabysmo also demonstrated rapid and robust drying of retinal fluid Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular...

Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment…

Ad hoc announcement pursuant to Art. 53 LRFood and Drug Administration (FDA) approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged 2 years and olderU.S. license holder Catalyst Pharmaceuticals plans for commercial launch in Q1-2024FDA approval triggers USD 36 million payment obligation from Catalyst to Santhera, of which USD 26 million will be used to cover Santhera's third-partymilestone obligationsFollowing the...

Nucleic Acid Amplification Testing Market to Reach $9.1 Billion, Globally, by…

Request Sample of the Report on Nucleic Acid Amplification Testing Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/180724 Request Sample of the Report on Nucleic Acid Amplification Testing Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/180724 Nucleic acid amplification testing is a laboratory technique for the detection and amplification of nucleic acids, such as DNA and RNA, from a sample. This method enables the quantification...

Advanced Wound Care and Closures Market to Reach $32.9 Billion, Globally, by…

Request Sample of the Report on Advanced Wound Care and Closures Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/94 Request Sample of the Report on Advanced Wound Care and Closures Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/94 Advanced wound care and closure methods are specifically developed to address and treat both chronic and acute wounds. Products like staples,sutures, adhesive tapes, sealants, and tissue adhesives serve...

Pompe Disease Market to Exhibit Significant Growth by 2032, Predicts…

Key Takeaways from the Pompe Disease Market Report Key Takeaways from the Pompe Disease Market Report Discover which therapies are expected to grab the major Pompe disease market share @Pompe Disease Market Report Pompe Disease Overview Pompe disease, alternatively referred to as glycogen storage disease type II (GSD II) or acid maltase deficiency (AMD), is a rare autosomal recessive metabolic disorder resulting from a deficiency of the acid alpha-glucosidase (GAA) enzyme...

Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023

Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023Mont-Saint-Guibert, Belgium – October 26, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2023 on Wednesday, November 8, 2023,...

Iba – Transparency Notification

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, October 26, 2023 18:00 Summary of the notificationION BEAM APPLICATIONS SA ("IBA") announces that it is required to make a transparency notification in accordance with Article 14, paragraph 1, of the Law on the Disclosure of Major Shareholdings in Issuers whose Shares are admitted to Trading on a Regulated Market and on Miscellaneous Provisions (the "Transparency...

Sandoz successfully issues CHF 750 million in inaugural bonds

Highly successful inaugural CHF senior bonds priced earlier todayTwo tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectivelyProceeds to partially repay bridge loan facility and for general corporate purposesBasel, October 26, 2023– Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750...

Portable Dishwasher Market Predicted to Reach US$ 6.4 billion by 2031, Garnering…

Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83818 Download PDF Brochure:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83818 High-end and designer portable dishwashers are gaining traction, catering to urban dwellers and individuals with limited kitchen space who seek both functionality and aesthetics. This niche market is ripe for expansion. The integration of smart technology, such as IoT...

Orexo´s Nomination Committee for the Annual General Meeting 2024

The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject "Nomination Committee") at latest February 24, 2024. The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com . Shareholders who want to submit proposals to the Nomination Committee…

A large international study of migraine reveals new biological pathways for…

Migraine is among the most common chronic pain disorders worldwide, with up to 20% of adults affected. Although recent advances have been made in studies of the genetics and underlying biology of migraine and new treatments recently developed that are effective for many migraine sufferers, they do not work for all types of migraine Migraine is among the most common chronic pain disorders worldwide, with up to 20% of adults affected. Although recent advances have been made in studies of the...

Veterinary Diagnostic Market Worth $5.0 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=26017452 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=26017452 Browse in-depth TOC on "Veterinary Diagnostic Market" 434 - Tables 23 - Figures 504 - Pages Veterinary Diagnostic Market Scope: The companion animal segment holds the largest market share during the forecast period. The veterinary diagnostics market is divided into...

Altri Comunicati